EU raises warning about GBS, or acute neuromuscular disease as a side effect after vaccination AstraZeneca but still very difficult to find
On September 8, 1964, the European Medicines Agency. Announcing the addition of Guillain-Barré syndrome (GBS) or acute neurological disease and muscle weakness. in the warning of possible side effects after vaccination against COVID-19 AstraZeneca
The European Medicines Agency says a causal relationship has been found between GBS and AstraZeneca’s vaccine. This is a reasonable possibility, after data as of July 31, 21, there were 833 cases of GBS from 592 million doses of AstraZeneca vaccination worldwide.
However, the European Medicines Agency has classified such side effects as “very rare”, with the lowest level of occurrence. And reiterating that the AstraZeneca vaccine still has the benefits outweighing the risks.
Earlier, the U.S. Food and Drug Administration (FDA) added a warning about possible GBS after Johnson & Johnson’s vaccination. The AstraZeneca and Johnson & Johnson vaccines It’s the same vaccine, the viral vector. which uses a virus as a vector and has been linked to thromboembolic events after vaccination as well.
Image – AFP Reference – https://www.reuters.com/article/health-coronavirus-vaccines-ema-idCNL4N2QA36O
Read related news.
– EU removes Thailand from list of countries safe from Covid-19
– Siriraj opens reservations for vaccinations AstraZeneca, the 1st dose for the general public 10-20 Sept.
– Ministry of Public Health opens adverse reactions after vaccination, all brands, cross-injection formula – 3 needles
.
